Literature DB >> 12548020

Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.

Cuider Allal1, Anne Pradines, Andrew D Hamilton, Said M Sebti, Gilles Favre.   

Abstract

Here we demonstrate that the geranylgeranyltransferase-I inhibitor GGTI-298 inhibits the RhoB pathway and disrupts stress fiber and focal adhesion formation in NIH-3T3 cells. Farnesylated (V14)RhoB-CAIM (resistant to GGTI-298), but not geranylgeranylated (V14)RhoB (-CLLL), prevented inhibition of actin stress fiber and focal adhesion formation, underlining the critical role of RhoB. In contrast, farnesylated, (V14)RhoA (-CVLS) was unable to prevent effects of GGTI 298 on cytoskeleton organization. Furthermore, the ability of GGTI-298 to induce p21(WAF) and to block cells in the G(0)/G(1) phase of the cell cycle was also prevented by farnesylated (V14)RhoB but not by farnesylated (V14)RhoA. Moreover, treatment with GGTI-298 of cells expressing farnesylated RhoB results in accumulation of these cells in the G(2)/M phase. Therefore, the RhoB pathway is a critical target of GGTI-298.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12548020     DOI: 10.4161/cc.1.6.272

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  12 in total

1.  Expansion of protein farnesyltransferase specificity using "tunable" active site interactions: development of bioengineered prenylation pathways.

Authors:  James L Hougland; Soumyashree A Gangopadhyay; Carol A Fierke
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

Review 2.  Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.

Authors:  Sherry S Agabiti; Yilan Liang; Andrew J Wiemer
Journal:  Mol Membr Biol       Date:  2016-08-18       Impact factor: 2.857

3.  RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.

Authors:  Laura A Marlow; Ilah Bok; Robert C Smallridge; John A Copland
Journal:  Endocr Relat Cancer       Date:  2015-07-23       Impact factor: 5.678

4.  Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.

Authors:  Guillaume Sarrabayrouse; Christine Pich; Raphaël Moriez; Virginie Armand-Labit; Philippe Rochaix; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

5.  Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

Authors:  Laura A Marlow; Lisa A Reynolds; Alan S Cleland; Simon J Cooper; Michelle L Gumz; Shinichi Kurakata; Kosaku Fujiwara; Ying Zhang; Thomas Sebo; Clive Grant; Bryan McIver; J Trad Wadsworth; Derek C Radisky; Robert C Smallridge; John A Copland
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

6.  Critical functions of RhoB in support of glioblastoma tumorigenesis.

Authors:  Yufang Ma; Yuanying Gong; Zhixiang Cheng; Sudan Loganathan; Crystal Kao; Jann N Sarkaria; Ty W Abel; Jialiang Wang
Journal:  Neuro Oncol       Date:  2014-09-12       Impact factor: 12.300

7.  Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I.

Authors:  Lai N Chan; Hannah D G Fiji; Masaru Watanabe; Ohyun Kwon; Fuyuhiko Tamanoi
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

8.  Inhibition of geranylgeranyl transferase-I decreases cell viability of HTLV-1-transformed cells.

Authors:  Dustin C Edwards; Katherine M McKinnon; Claudio Fenizia; Kyung-Jin Jung; John N Brady; Cynthia A Pise-Masison
Journal:  Viruses       Date:  2011-10-10       Impact factor: 5.048

9.  RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.

Authors:  Zsolt Sebestyen; Wouter Scheper; Anna Vyborova; Siyi Gu; Zuzana Rychnavska; Marleen Schiffler; Astrid Cleven; Coraline Chéneau; Martje van Noorden; Cassie-Marie Peigné; Daniel Olive; Robert Jan Lebbink; Rimke Oostvogels; Tuna Mutis; Gerrit Jan Schuurhuis; Erin J Adams; Emmanuel Scotet; Jürgen Kuball
Journal:  Cell Rep       Date:  2016-05-19       Impact factor: 9.423

10.  In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.

Authors:  Drazen B Zimonjic; Lai N Chan; Veenu Tripathi; Jie Lu; Ohyun Kwon; Nicholas C Popescu; Douglas R Lowy; Fuyuhiko Tamanoi
Journal:  BMC Cancer       Date:  2013-04-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.